5-α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population-based cohort study.
5αRIs
anaemia
benign prostatic hyperplasia
haematology
α-blockers
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
29
01
2022
received:
19
07
2021
accepted:
26
02
2022
pubmed:
19
3
2022
medline:
20
7
2022
entrez:
18
3
2022
Statut:
ppublish
Résumé
5-α reductase inhibitors (5αRIs) are effective for the treatment of benign prostatic hyperplasia (BPH). However, 5αRIs could lower levels of haemoglobin, increasing the risk of anaemia. The objective of this study was to compare the rate of anaemia between new users of 5αRIs and α-blockers in the UK. We conducted a matched, active comparator, new-user cohort study using the Clinical Practice Research Datalink. The study population consisted of men aged ≥40 years with incident BPH who initiated 5αRIs between 1998 and 2019 and were matched 1:1 on propensity score to new users of α-blockers. Anaemia was defined by a measured haemoglobin <130 g/L. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for anaemia. Our study cohort included 9429 new users of 5αRIs and 9429 matched new users of α-blockers. Their median durations of follow-up were 136 days (interquartile range: 54-336 d) and 77 days (interquartile range: 58-236 d), respectively. A total of 2865 5αRIs users and 2407 α-blocker users developed incident anaemia, representing rates of 37.3 (95% CI: 33.6-41.3) and 42.0 (95% CI: 38.1-46.2) per 100 person-years, respectively. The use of 5αRIs was not associated with an increased risk of anaemia compared to the use of α-blockers (HR: 0.95, 95% CI: 0.90-1.00). Similarly, we did not observe an increased risk of mild, moderate, or severe anaemia. The use of 5αRIs was not associated with an increased risk of anaemia compared to the use of α-blockers among men with BPH.
Substances chimiques
5-alpha Reductase Inhibitors
0
Adrenergic alpha-Antagonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3771-3781Informations de copyright
© 2022 British Pharmacological Society.
Références
McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793-1803. doi:10.1016/j.juro.2011.01.074
McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557-563. doi:10.1056/NEJM199802263380901
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434-441. doi:10.1016/S0090-4295(02)01905-2
MacDonald D, McNicholas TA. Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life. Drugs. 2003;63(18):1947-1962. doi:10.2165/00003495-200363180-00004
Finn DA, Beadles-Bohling AS, Beckley EH, et al. A new look at the 5α-reductase inhibitor finasteride. CNS Drug Rev. 2006;12(1):53-76. doi:10.1111/j.1527-3458.2006.00053.x
Hero M, Wickman S, Hanhijarvi R, Siimes MA, Dunkel L. Pubertal upregulation of erythropoiesis in boys is determined primarily by androgen. J Pediatr. 2005;146(2):245-252. doi:10.1016/j.jpeds.2004.09.002
Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab. 1972;34(4):730-735. doi:10.1210/jcem-34-4-730
Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589-598. doi:10.1210/jcem.87.2.8201
Ornstein DK, Beiser JA, Andriole GL. Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int. 1999;83(1):43-46. doi:10.1046/j.1464-410x.1999.00844.x
Weber JP, Walsh PC, Peters CA, Spivak JL. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol. 1991;36(3):190-194. doi:10.1002/ajh.2830360306
Hicks BM, Klil-Drori AJ, Yin H, Campeau L, Azoulay L. Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer. Epidemiology. 2017;28(5):712-718. doi:10.1097/EDE.0000000000000678
Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2670-2677. doi:10.1210/jc.85.8.2670
Shin YS, You JH, Cha JS, Park JK. The relationship between serum total testosterone and free testosterone levels with serum hemoglobin and hematocrit levels: a study in 1221 men. Aging Male. 2016;19(4):209-214. doi:10.1080/13685538.2016.1229764
Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N EnglJ Med. 2010;363(2):109-122. doi:10.1056/NEJMoa1000485
Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510. doi:10.1210/jc.85.12.4500
Waalen J, von Lohneysen K, Lee P, Xu X, Friedman JS. Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause. Eur J Haematol. 2011;87(2):107-116. doi:10.1111/j.1600-0609.2011.01631.x
Beer TM, Tangen CM, Bland LB, et al. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894. Cancer. 2006;107(3):489-496. doi:10.1002/cncr.22029
Kouriefs C, Betambeau N, Rowbotham C, Coyne K, Rowley M, Jones CR. Finasteride-induced thrombocytopenia. BJU Int. 2002;90(3):348-349. doi:10.1046/j.1464-410X.2002.02851.x
Figueira-Coelho J, Pereira O, Picado B, Mendonca P, Neves-Costa J, Neta J. Acute hepatitis associated with the use of levofloxacin. Clin Ther. 2010;32(10):1733-1737. doi:10.1016/j.clinthera.2010.09.004
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920. doi:10.1093/aje/kwg231
Williams T, Van Staa TP, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf. 2012;3(2):89-99. doi:10.1177/2042098611435911
Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827-836. doi:10.1093/ije/dyv098
Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4-14. doi:10.1111/j.1365-2125.2009.03537.x
Rivero JR Jr, Thompson IM Jr, Liss MA, Kaushik D. Chemoprevention in Prostate Cancer: Current Perspective and Future Directions. Cold Spring Harb Perspect Med. 2018;8(10):1-8. doi:10.1101/cshperspect.a030494
Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J am Acad Dermatol. 1999;41(4):550-554.
World Health Organization. Worldwide prevalence of anaemia 1993-2005: WHO Global Database on Anaemia. World Health Organization; 2008: 4-25. https://www.who.int/publications/i/item/9789241596657
Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079. discussion 81-90, 10. doi:10.1016/0895-4356(93)90103-8
Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived rom ICD-9-CCM administrative data. Med Care. 2002;40(8):675-685. doi:10.1097/00005650-200208000-00007
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. MedCare. 2005;43(11):1130-1139. doi:10.1097/01.mlr.0000182534.19832.83
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619. doi:10.1016/0895-4356(92)90133-8
Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149-1156. doi:10.1093/aje/kwj149
Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics. 1995;51(4):1469-1482. doi:10.2307/2533277
Wang SV, Verpillat P, Rassen JA, Patrick A, Garry EM, Bartels DB. Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases. Clin Pharmacol Ther. 2016;99(3):325-332. doi:10.1002/cpt.329
R Core Team. R: A language and environment for statistical computing. 3.4.2 ed. R Foundation for Statistical Computing; 2018. https://www.r-project.org/
Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-1843. doi:10.1056/NEJMra1401038
Kassebaum NJ, Collaborators GBDA. The Global Burden of Anemia. Hematol Oncol Clin North am. 2016;30(2):247-308. doi:10.1016/j.hoc.2015.11.002
Hershko C, Karsai A, Eylon L, Izak G. The effect of chronic iron deficiency on some biochemical functions of the human hemopoietic tissue. Blood. 1970;36(3):321-329. doi:10.1182/blood.V36.3.321.321
Anand IS. Anemia and chronic heart failure implications and treatment options. J am Coll Cardiol. 2008;52(7):501-511. doi:10.1016/j.jacc.2008.04.044
Thein M, Ershler WB, Artz AS, et al. Diminished quality of life and physical function in community-dwelling elderly with anemia. Medicine (Baltimore). 2009;88(2):107-114. doi:10.1097/MD.0b013e31819d89d5
Robinson B. Cost of anemia in the elderly. J am Geriatr Soc. 2003;51(3 Suppl):S14-S17. doi:10.1046/j.1532-5415.51.3s.5.x
Gao W, Kearbey JD, Nair VA, et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology. 2004;145(12):5420-5428. doi:10.1210/en.2004-0627
Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221-228. doi:10.1007/s40471-015-0053-5
Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar Behav Res. 2011;46(3):399-424. doi:10.1080/00273171.2011.568786
Kim EH, Brockman JA, Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol. 2018;5(1):28-32. doi:10.1016/j.ajur.2017.11.005